Cotherix

About:

CoTherix, Inc. operates as a development stage company that engages in biopharmaceutical operations.

Top Investors: Sofinnova Partners, MPM Capital, Vivo Capital, Sofinnova Investments, Frazier Healthcare Partners

Description:

Cotherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, our lead product candidate, is an inhaled formulation of iloprost.

Total Funding Amount:

$55M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2000-01-01

Founders:

David Cory

Number of Employees:

51-100

Last Funding Date:

2003-10-14

IPO Status:

Delisted

Industries: